In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
|Podcasts|June 25, 2020
ARVO 2020: Two-year anatomical outcomes of FAc in DME patients
Author(s)Alex Delaney-Gesing
Advertisement
Victor Gonzalez, MD, speaks with Ophthalmology Times® David Hutton on the highlights of his presentation regarding "Two-year outcomes from the PALADIN Phase 4 study: Anatomic/functional changes and reduced treatment frequency associated with 0.19 mg of fluocinolone acetonide implant (FAc) with persistent or recurrent diabetic macular edema," during the 2020 Association for Research in Vision and Ophthalmology (ARVO) virtual meeting.
Advertisement
Related to this article
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
What the approval of a second targeted biologic means for patients, practice, and the evolving TED treatment landscape
Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Comments from the FDA Advisory Committee meeting on SYD-101
2
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
3
FAQ: Diabetic eye disease awareness month 2026
4
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
5